Metabolic syndrome (MetS) is a cluster of metabolic abnormalities that includes hypertension, central obesity, insulin resistance, and atherogenic dyslipidemia. American Heart Association (AHA) and National Heart, Lung, and Blood Institute (NHLBI) criteria are widely used for the diagnosis of MetS that require the presence of any 3 out of 5 metabolic traits for the diagnosis. These include: hypertension (>130/85 mmHg), abdominal obesity (a waist circumference of ≥102 cm in men, ≥88 cm in women, elevated triglycerides (TG ≥150 mg/dl), reduced plasma high-density lipoprotein cholesterol (HDL <40 mg/dl in men and <50 mg/dl in women), and impaired glucose tolerance (>100 mg/dl). The MetS prevalence was three times higher, marking about one- third of the American adult population. Recently, the National Health and Nutrition Examination Survey (NHANES) released recent data demonstrating declining numbers of the disease with 24% in men and 22% in women. The novel adipokine lipocalin-2 (LCN-2) is a glycoprotein consisting of 198 amino acids. Other names attributed to LCN-2 include siderocalin, neutrophil gelatinase-associated lipocalin (NGAL), and uterocalin. LCN-2 is a member of the lipocalin superfamily, a group of circulatory proteins that transport small and hydrophobic molecules such as steroids, fatty acids, retinoids, prostaglandins and hormones. The expression of LCN-2 is stimulated during 3T3-L1 adipogenesis in a CCAAT/enhancer-binding protein–dependent manner. White adipose tissue (WAT) was the major source of LCN-2 expression and reported its absence in brown adipose tissue (BAT) in wild-type male mice. They suggested that obesity regulates its expression. Fetuin-A, also referred to as α2-Heremans–Schmid glycoprotein (AHSG), is a protein with pleiotropic metabolic effects secreted by the liver. Fetuin-A is a potential adipokine, its expression and secretion levels have been increased in visceral adipose tissue humans with MetS. MiR-17-5p and miR-15a-5p, were found to be the strongest predictors of MetS presence, as their expression panel was decreased in individuals with MetS, independent of sex.